NEW YORK, Sept. 20, 2023 /PRNewswire/ -- The biobanking market is expected to grow by USD 1.45 billion from 2022 to 2027. In addition, the market's momentum will progress at a CAGR of 8.58% during the forecast period, according to Technavio Research. The market is segmented by Type (Physical and Virtual), Product (Equipment and Consumables), and Geography (Europe, North America, Asia, and the Rest of the World (ROW)). Europe is estimated to contribute 38% to the growth of the global market during the forecast period. A growing need for the preservation of biosamples in Europe has been driven by the presence of many well-known Biobanks within the region. This is a result of the very robust biobanking system, for example, in Nordic countries such as Sweden, Norway, Denmark, Finland, Iceland, and other EU countries like France and Belgium. The two main factors that support these countries with strong biobank systems in the region are high-quality biobanks and efficient public health services. The UK's Biobank, with a population of more than 5 million samples, is one of the most important biobanks in the region and has proved to be vital for conducting major-scale drug research. Hence, these factors are expected to drive market growth during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE PDF Sample Report
Company Profile:
AMS Biotechnology Europe Ltd., ASKION GmbH, Azenta Inc., Bay Biosciences LLC, BioIVT LLC, Boca Biolistics LLC, CTIBiotech, Cureline Inc., Danaher Corp., Firalis SA, GENETICIST Inc., Greiner Bio One International GmbH, Hamilton Bonaduz AG, OraSure Technologies Inc., PHC Holdings Corp., Promega Corp., ProteoGenex Inc., Shanghai Genext Medical Technology Co. Ltd., Thermo Fisher Scientific Inc., and US Biolab Corp. Inc.
AMS Biotechnology Europe Ltd. - The company offers biobanking such as Pig Liver Total RNA, Zebrafish Genomic DNA, Human tonsil normal FFPE tissue block, and others.
To gain access to more vendor profiles available with Technavio, buy the report!
Biobanking Market: Segmentation Analysis
The market share growth by the physical segment will be significant during the forecast period. Based on the physical nature of the biological samples, the physical segment refers to the various types of biobanks. Biobanks can be divided into several groups, e.g. tissue biobanks, stem cell banks, and blood branches, as a result of the biological characteristics of the sample.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Biobanking Market: Market Dynamics
Key Driver
- Growing demand for personalized medicine
- Increase in efficiency through automation
- Reduction in research costs
Growing demand for personalized medicine is a key factor driving market growth. Personalized medicine refers to treatments that are based on an individual's characteristics, needs, and preferences. People are increasingly saving their tissue and stem cells for future treatment if needed. An important need for personalized medicine is the availability of individual samples containing individual annotated clinical and pathological data. Furthermore, research institutions are widely exploring ways to develop personalized treatments from biological samples. For example, in February 2021, UPS Healthcare announced an investment and further expansion of its capabilities in genetic and cellular services. Additionally, in June 2020, Infosys, a next-generation digital consulting and services company, launched personalized medicine solutions for the pharmaceutical industry. Hence, these factors are expected to drive market growth during the forecast period.
Increasing focus on rare disease research is a major trend in the market. Identify key trends, drivers, and challenges in the market. Download a FREE sample to gain access to this information.
FAQS
- How do the major trends impact the market?
- How big is the Europe market?
- How do the key drivers and challenges impact the market?
Related Reports:
The bioprocess validation market size is estimated to grow at a CAGR of 11.39% between 2022 and 2027. The market size is forecast to increase by USD 280.93 million. This bioprocess validation market report extensively covers market segmentation by end-user (pharmaceutical companies, contract development and manufacturing organizations, and others), type (in-house and outsourced), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). One of the key factors driving the bioprocess validation market growth is the increasing demand for biopharmaceuticals.
Biochips Market size is estimated to grow by USD 43,273.01 million between 2022 and 2027 accelerating at a CAGR of 25.15% during the forecast period. This biochips market report extensively covers market segmentation by end-user (biotechnology and pharmaceutical companies, hospitals and diagnostics centers, and academic and research institutes), technology (microarrays and microfluidics), and geography (North America, Europe, APAC, Middle East and Africa, and South America). The growing use of personalized medicines is notably driving the market growth.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Type
Market Segmentation by Product
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
![](https://rt.prnewswire.com/rt.gif?NewsItemId=CG13889&Transmission_Id=202309201915PR_NEWS_USPR_____CG13889&DateId=20230920)
Share this article